Plant Name: Phegopteris bukoensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GPBAR1; | |
| PTPN1; PTPN2; ACP1; PTPRF; | |
| GLA; FAAH; RECQL; TDP1; TERT; GLO1; HSD11B1; ALOX12; AKR1B1; HSD17B10; ALOX15; AKR1B10; NOX4; TNKS; PARP1; TNKS2; POLB; CD38; | |
| GSK3B; FLT3; | |
| CA2; CA12; CA1; CA9; CA3; CA5B; CA7; CA5A; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| RORC; | |
| NR1H4; | |
| ALOX5; MAOA; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| TLR2; | |
| HIF1A; TP53; | |
| ABCG2; | |
| LMNA; FABP5; TTR; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.484E-09 | 1.154E-06 | AKR1B1, AKR1B10, ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, GSK3B, HSD11B1, HSD17B10, KDM4E, MAOA, NOX4, PPARD, PPARG, XDH |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 7.680E-08 | 2.883E-05 | AKR1B1, AKR1B10, APP, CYP1A1, CYP1A2, CYP1B1, HSD11B1, NR1H4, PPARD |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 4.554E-07 | 1.502E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.174E-07 | 1.657E-04 | CYP1A1, POLB, PPARG, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.031E-07 | 2.126E-04 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.167E-06 | 3.099E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.657E-06 | 5.903E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
| BP | GO:0008152; metabolic process | GO:1901564; organonitrogen compound metabolic process | 3.444E-06 | 7.353E-04 | ABCG2, ACP1, AKR1B1, APP, CD38, CYP1A1, CYP1A2, FLT3, GLA, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, MAOA, MMP12, MMP2, MMP9, NOX4, NR1H4, PARP1, POLB, PPARA, PPARD, PPARG, PTPN1, PTPN2, PTPRF, TLR2, TNKS, TNKS2, TP53, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.540E-06 | 7.483E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 5.774E-06 | 1.143E-03 | AKR1B1, ALOX15, APP, CA2, CYP1A1, CYP1A2, CYP1B1, FABP5, FLT3, GSK3B, HIF1A, HSD11B1, LMNA, MMP9, POLB, PPARA, PPARD, PPARG, PTPRF, RORC, SMN1, SMN2, TLR2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 9.506E-06 | 1.729E-03 | AKR1B10, CYP1A1, CYP1B1, PPARD, TTR |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.810E-06 | 1.729E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.810E-06 | 1.729E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:2001242; regulation of intrinsic apoptotic signaling pathway | 1.043E-05 | 1.817E-03 | HIF1A, MMP9, PARP1, PTPN1, PTPN2, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.217E-05 | 2.055E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.327E-05 | 2.206E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.530E-05 | 2.432E-03 | CYP1B1, GLA, HIF1A, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.630E-05 | 2.544E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.696E-05 | 2.619E-03 | ABCG2, AKR1B1, CA3, CA9, CD38, CYP1A1, CYP1B1, POLB, PPARG, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 1.747E-05 | 2.679E-03 | AKR1B10, CYP1B1, FAAH, FABP5, GLA, PPARD |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.923E-05 | 2.868E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.975E-05 | 2.905E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 2.053E-05 | 2.961E-03 | AKR1B1, CA9, CD38, PARP1, PPARG, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.529E-05 | 3.576E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.937E-05 | 3.876E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 3.876E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 2.937E-05 | 3.876E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.937E-05 | 3.876E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.937E-05 | 3.876E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 2.937E-05 | 3.876E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.125E-05 | 4.075E-03 | NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 3.323E-05 | 4.269E-03 | ALOX12, APP, CD38, GSK3B, HIF1A, LMNA, NR1H4, PPARD, PPARG, PTPN2, TERT, TLR2, XDH |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 3.327E-05 | 4.269E-03 | APP, GSK3B, HIF1A, PARP1, PTPN1, PTPN2, PTPRF, TERT, TP53, XDH |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 3.373E-05 | 4.295E-03 | ABCG2, AKR1B1, AKR1B10, APP, CA4, CA5A, CA5B, CD38, CYP1A1, CYP1A2, CYP1B1, FLT3, GLA, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, LMNA, MAOA, MMP12, MMP2, NOX4, PARP1, POLB, PPARA, PPARD, PPARG, PTPN1, PTPN2, RECQL, RORC, SMN1, SMN2, TDP1, TERT, TLR2, TNKS, TNKS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.827E-05 | 4.817E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 4.422E-05 | 5.409E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 4.422E-05 | 5.409E-03 | MMP2, MMP9, TERT |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 4.686E-05 | 5.637E-03 | AKR1B1, ALOX15, APP, CYP1B1, FLT3, NOX4, PPARD, PTPN1, PTPN2, TLR2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.073E-05 | 5.972E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.073E-05 | 5.972E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.622E-05 | 6.512E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 5.785E-05 | 6.513E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 5.862E-05 | 6.513E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 5.862E-05 | 6.513E-03 | PTPN1, PTPN2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 5.862E-05 | 6.513E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.862E-05 | 6.513E-03 | CYP1A1, CYP1A2 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 5.944E-05 | 6.570E-03 | APP, CYP1B1, GLA, GSK3B, MMP9, NR1H4, PPARA, PPARG, PTPN1, PTPN2, PTPRF, TNKS, TP53 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 6.302E-05 | 6.930E-03 | CD38, HIF1A, NR1H4, PPARD |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 6.559E-05 | 7.106E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 6.759E-05 | 7.286E-03 | AKR1B1, CD38, MMP2, NR1H4, PPARG, TLR2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 7.398E-05 | 7.782E-03 | PARP1, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.791E-05 | 8.117E-03 | CA2, CA7, HIF1A, NR1H4, TNKS, TNKS2 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 8.304E-05 | 8.489E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 8.304E-05 | 8.489E-03 | APP, GSK3B, PARP1 |
| BP | GO:0051179; localization | GO:0046903; secretion | 8.856E-05 | 9.011E-03 | ALOX5, APP, CA2, CA9, FABP5, GLA, HIF1A, MMP9, NR1H4, TLR2, TTR, XDH |
| CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 9.097E-05 | 9.214E-03 | ABCG2, ACP1, AKR1B1, AKR1B10, ALOX12, ALOX15, ALOX5, APP, CA1, CA2, CA3, CA4, CA5A, CA5B, CA7, CYP1A1, CYP1A2, CYP1B1, FAAH, FABP5, FLT3, GLA, GLO1, GSK3B, HIF1A, HSD11B1, HSD17B10, LMNA, MAOA, MMP2, MMP9, NOX4, PARP1, PPARG, PTPN1, PTPN2, SMN1, SMN2, TERT, TLR2, TNKS, TNKS2, TP53, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.750E-05 | 9.607E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.750E-05 | 9.607E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.025E-04 | 9.927E-03 | ALOX15, PPARA, PPARD, TP53 |
| MF | GO:0005488; binding | GO:0035257; nuclear hormone receptor binding | 1.039E-04 | 9.927E-03 | FLT3, HIF1A, NR1H4, PARP1, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.346E-22 | 1.465E-18 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.083E-17 | 5.896E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.037E-16 | 4.517E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.378E-16 | 5.003E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, PPARD, PPARG, PTPN1, RORC, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.128E-22 | 8.641E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.592E-06 | 4.647E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.638E-05 | 8.283E-04 | GSK3B; FLT3; MMP2; PPARG; HIF1A; TP53; MMP9; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.333E-05 | 8.283E-04 | APP; MAOA; ALOX5; ALOX15; ALOX12 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.937E-05 | 8.283E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.283E-05 | 1.467E-03 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.837E-05 | 1.372E-03 | FABP5; PPARG; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.115E-04 | 3.660E-03 | HSD11B1; AKR1B10; MAOA; ALOX5; CYP1A2; ALOX15; CYP1A1; CD38; AKR1B1; ALOX12; HSD17B10; XDH |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.846E-04 | 3.874E-03 | MMP2; TP53; HIF1A; MMP9; TLR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.147E-04 | 1.617E-03 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.430E-04 | 3.720E-03 | PTPN1; GSK3B; PPARA; PTPRF |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.650E-04 | 3.396E-03 | MMP2; MMP9; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.034E-04 | 1.617E-03 | AKR1B10; AKR1B1; GLA |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.778E-04 | 4.491E-03 | ALOX5; CYP1A1; CYP1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.772E-04 | 6.849E-03 | AKR1B10; AKR1B1; GLA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.983E-04 | 7.450E-03 | ALOX5; ALOX15; ALOX12 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.126E-03 | 8.817E-03 | FLT3; TP53; HIF1A |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.500E-03 | 1.058E-02 | PTPN1; ACP1; PTPRF |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.220E-03 | 1.424E-02 | FLT3; PPARG; TP53; MMP9 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.331E-03 | 9.880E-03 | CA2; NR1H4; ABCG2 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.942E-03 | 3.733E-02 | POLB; GSK3B; TERT; TP53 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.618E-03 | 2.829E-02 | GSK3B; TP53; HIF1A |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.812E-03 | 3.733E-02 | GSK3B; PPARA; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.986E-03 | 3.840E-02 | PARP1; LMNA; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 8.303E-03 | 3.777E-02 | GSK3B; TP53; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.007E-02 | 4.057E-02 | TP53; MMP9; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.340E-03 | 3.873E-02 | GSK3B; TP53; PPARD |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 8.813E-03 | 3.840E-02 | PTPN1; GSK3B; PTPRF |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.523E-03 | 2.070E-02 | PPARG; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.100E-02 | 4.309E-02 | GSK3B; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.311E-02 | 4.866E-02 | FLT3; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.523E-03 | 2.070E-02 | CYP1A2; ALOX15 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.225E-02 | 4.668E-02 | GSK3B; TP53 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 5.393E-03 | 2.816E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 4.279E-03 | 2.413E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.546E-03 | 2.465E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.221E-03 | 1.424E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.097E-05 | 1.603E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12; FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOA; PPARG; PPARG; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| NA: NA | Edema | NA | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; MAOA; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PPARG |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH; MAOA |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; PARP1; TLR2 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; MMP9; CA9; MMP2; TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; HSD11B1; HSD11B1; AKR1B1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
| C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; HIF1A; TP53; CA1; FLT3; FLT3; MMP9; CA9; PARP1; MMP2; CD38; APP; TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; TERT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; HSD11B1; PPARD; MMP12 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; PARP1; MMP2 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TERT; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TERT; MMP2; TLR2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |